Page 162 - CW E-Magazine (13-2-2024)

News from Abroad News from Abroad

FOCUS ON RENEWABLES Encapsulant Sheet Market – 2024: porary shortage in EVA. Since then, and co-founder, Mr. Stephen Moore.
Sustainable ingredients fi rm, Future Origins, updates A fast-growing market undergoing POE usage has continued to grow, Another key fi nding of the report is
rapid transformation.”
primarily due to the performance the forecast globalisation of encapsulant
requirements of the latest generation sheet production due to regional and
on pilot scale activities The report estimates the global of TOPCon cell structure-based solar national initiatives such as the U.S.
solar encapsulant sheet market at in modules. “Potential-induced degrada- Infl ation Reduction Act (IRA) and
Future Origins, a US-based joint excess of 1.7-mt in 2023, with around tion, or PID, concerns are the chief local content requirements in India,
venture that is commercialising sus- 28% of the market being POE. The driver in the uptake of POE as an and trade-related barriers such as anti-
tainable alternatives to critical ingre- base case scenario also forecasts encapsulant materia,l but as this mate- dumping duties implemented in Europe
dients in the formulations of everyday growth averaging over 7% per annum rial is now priced signifi cantly higher and elsewhere.
cosmetics, personal care and cleaning over the next decade. than EVA, sheet makers are innovating
products, was formally launched at the alternatives,” said Mr. John Gugel, ducts, as well as supply derivatives to with multi-layer structure that com- The share of sheet production out-
American Cleaning Institute’s 2024 CEO, Future Origins. its chemical business customers,” said 2021 marked a signifi cant increase bine POE with EVA to achieve the side of China is estimated to reach
convention held in Orlando, Florida, Mr. Masahiro Katayose, Senior Execu- in adoption of POE as a solar encapsu- right balance of price versus perfor- almost 35% by 2032 in the base case
recently. Future Origins will use Geno’s fer- tive Offi cer, President, Chemical Busi- lation material, primarily due to a tem- mance,” said MLT Analytics CEO derived from MLTA modelling.
mentation-based technology and pro- ness at Kao.
Future Origins was founded by prietary engineered microorganisms to Novonesis established as Novozymes-Chr. Hansen
industrial biotechnology fi rm Geno, produce more sustainable surfactants. “We are thrilled to see Future Ori-
FMCG major Unilever, Japanese cos- Future Origins’ high-volume drop-in gins achieve this signifi cant milestone merger complete
metics company Kao, and French beauty replacement ingredients will have a with our joint efforts, propelling us
giant L’Oréal, to commercialise and signifi cantly lower carbon footprint towards our vision of a more sustain- The proposed combination of the Business Authority, the company nue performance will be provided
manufacture high-volume sustainable than their current counterparts and will able and responsible beauty industry,” legacy companies Novozymes and said. The combined company brings for the following sales areas:
ingredients for widely used surfactants also align with increasing regulatory said Mr. Mohamed Kanji, Chief Open Chr. Hansen was successfully com- together 10,000 people worldwide  Food & Health Biosolutions:
such as laundry detergent and face requirements and corporate commitments Innovation Offi cer and Operational pleted on January 29, 2024, esta- and an expertise that spans more • ‘Food & Beverages’ (Novozymes’
wash. for a deforestation-free supply chains. Excellence for North America at L’Oréal. blishing the company, Novonesis. than 30 different industries. Food & Beverage and Chr. Hansen’s
On December 12, 2022, Danish bio- Food Cultures & Enzymes).
Future Origins said its recently Mr. Richard Slater, Chief Research While product development acti- tech firms, Novozymes and Chr. The combined group will have • ‘Human Health’ (Novozymes’
completed 63,000-litre pilot-scale fer- and Development Offi cer at Unilever, vities continue, Future Origins plans to Hansen, entered into an agreement annual revenue of approximately Human Health and Chr. Hansen’s
mentation runs have produced several said: “We have invested in Future have the fi rst commercial-scale manu- to create a global biosolutions firm €3.7-bn. Half of the group’s port- Human Health).
tonnes of material. A fraction of that Origins because we believe in using facturing plant under construction through a statutory merger of the two folio will focus on enabling healthier  Planetary Health Biosolutions:
was further processed to make hundreds science to help us transition to ingre- by 2025. Under the current timeline, companies. lives and producing better foods. • ‘Agriculture, Energy & Tech’
of kilograms of detergent alcohols. dient sourcing routes that are sustain- Future Origins will start full-scale The other half will address reducing (Novozymes’ Bioenergy, Agriculture &
Future Origins is shipping these products able for the long term. Biotechnology production within by 2028. All regulatory approvals and regi- chemical use and targeting climate Animal Health/ Nutrition, Grain &
to commercial partners for use in a variety sits at the intersection of science and strations have been received and neutral practices. Tech Processing and Chr. Hansen’s
of applications. This run provides criti- sustainability and holds huge potential “We look forward to meeting and the proposed combination has been Animal & Plant Health).
cal data necessary for the design of its for futureproofi ng our business, as well working with industry partners interes- successfully completed following Revenue will be reported for two • ‘Household Care’ (Novozymes’
fi rst commercial plant, anticipated to as the planet.” ted in gaining early access to these the fi nal registration with the Danish divisions. For each, additional reve- Household Care).
start operations in less than fi ve years. sustainable products and reserving
“Through our partnership with capacity in the commercial scale plant,” HEALTHCARE
“We are at a moment in time where Future Origins, Kao aims to produce said Dr. Priti Pharkya, Senior Vice
the innovation in biotechnology is more sustainable ingredients for use President of Business Operations at DKSH announces acquisition in Brunei
meeting the demand for sustainable in our home and personal care pro- Future Origins.
Switzerland-based DKSH has for the last 25 years. It dis-
INDUSTRY TRENDS agreed to acquire Medipharm, one of tributes pharmaceutical
New solar cell technologies accelerate a transfor- the leading pharmaceutical and medi- products, medical devices,
consumer health, personal
cal devices distributors in Brunei. The
mational shift in encapsulant sheet adoption: Report acquisition is in line with DKSH’s care, and nutritional pro-
Healthcare division’s strategy to ducts. Its main customers
Ethylene-vinyl acetate (EVA) and sulation of solar modules, albeit with takeaway from Singapore-based MLT expand its footprint in the Asia-Pacifi c are hospitals, medical cen-
polyolefi n elastomer (POE) will co- various twists and turns anticipated Analytics’ (MLTA’s) new report enti- region. Medipharm, has been operating tres, clinics, opticians, and
exist as the materials of choice for encap- over the next decade. This is the key tled “Global EVA/POE Solar Module as DKSH’s sub-distributor in Brunei pharmacies.

162 Chemical Weekly February 13, 2024 Chemical Weekly February 13, 2024 163

Contents Index to Advertisers Index to Products Advertised